Conatus Pharmaceuticals Inc. (CNAT) stock is exploding higher by more than 44% Thursday, as the biotechnology firm today announced top-line results from nonalcoholic fatty liver disease /nonalcoholic steatohepatitis [NAFLD/NASH] clinical trial of Emricasan, a first-in-class, orally active pan-caspase protease inhibitor.
“With these results from the NAFLD/NASH trial, we have confirmed that the optimal dose of emricasan is consistent across different etiologies,” said in a statement Conatus co-founder, President and CEO, Steven J. Mento, Ph.D., “and strengthened our belief that inhibiting excessive apoptosis and inflammation will be therapeutic in patients whose liver damage is associated with NASH.”
CNAT shares recently gained $2.60 to $8.35. In the past 52 weeks, shares of San Diego, California-based company have traded between a low of $5.06 and a high of $11.74. Shares are down 39.18% year-over-year and 17.71% year-to-date.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!